Advances In The Mechanism And New Therapies Of Alopecia Areata

    October 2023 in “ International journal of rheumatic diseases ”
    Yi Jin, Zhiyong Guo, Weihua Pan … Qiang Tong
    Studysummary This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 14

    1. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    2. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    3. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis Acta dermato-venereologica · 2023
    4. Alopecia Areata and Risk of Atopic and Autoimmune Conditions: Population-Based Cohort Study Clinical and Experimental Dermatology · 2022
    5. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    6. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    7. The Associated Burden of Mental Health Conditions in Alopecia Areata: A Population-Based Study in UK Primary Care British Journal of Dermatology · 2022
    8. Treatment of Pediatric Alopecia Areata: A Systematic Review Journal of the American Academy of Dermatology · 2021
    9. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    10. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    11. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    12. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    13. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    14. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012

    Related research 5

    1. Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata JAAD case reports · 2019
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Linear Alopecia Areata JAAD case reports · 2018
    4. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    5. Overview of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013